"We have incredible data based on long-term follow up that help us understand what the right therapy is for kids, primarily kids with neurologic diseases like spina bifida," says Rosalia Misseri, MD, FAAP.
In this interview, Rosalia Misseri, MD, FAAP, highlights ongoing efforts to enhance quality of life for pediatric patinets with urologic diseases through long-term data. Misseri is the chief of pediatric urology at Riley Children’s Health at Indiana University Health in Indianapolis.
Video Transcript:
I think we're doing some incredible work here looking at the long-term outcomes of different pediatric urologic diseases, and using that information to bring it back to the newborn and work with optimizing care from the minute the child is born. We have incredible data based on long-term follow up that help us understand what the right therapy is for kids, primarily kids with neurologic diseases like spina bifida, where there's a lot of focus on protecting their kidneys and optimizing the function of their bladder. But also, what we're learning is how important continence is to people with diseases that cause them to be incontinent and trying to optimize the appropriate time to intervene. How do we decide how important incontinence is to the child? How do we decide how important incontinence is to the family and how it affects their day to day life?
This transcription has been edited for clarity.
Pediatric urinary microbiome composition is associated with recurrent UTI
September 10th 2024“We hope to learn more about the urinary tract and then be able to correlate predisposition to UTIs or other urological conditions with urobiome composition or marker microbe presence,” says Tatyana A. Sysoeva, PhD.
ER utilization and overtreatment for UTI in pediatric patients with spina bifida
July 16th 2024"We've been working with families and other providers to learn the diagnostic criteria for what makes a urinary tract infection and to avoid treating when it's unnecessary," says Briony K. Varda, MD, MPH.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.